This content is machine translated Highlights from the AAD Annual Meeting Atopic Dermatitis: Interesting News on Drug Candidates in Phase III At the 2026 Annual Meeting of the American Academy of Dermatology (AAD), the latest study data on amlitelimab and rademikibart, among other topics, were presented during Late-Breaking Research sessions. The...…
View Post 3 min This content is machine translated Psoriasis Research: What's in the Pipeline? Highly selective oral TYK inhibitors in Phase III Envudeucitinib and Zasocitinib are oral, allosteric tyrosine kinase 2 (TYK2) inhibitors currently being evaluated in clinical trials for plaque psoriasis. The interim results presented during the Late-Breaking Research sessions at...…
